Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)
Close on Nov 18, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Inhibikase Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $38.24M, up 40.8% year over year. For fiscal 2025 it was $29.79M, up 73.1% from the year before. The highest annual figure on record is $29.79M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.79M | +73.1% |
| FY2024 | Dec 31, 2024 | $17.21M | +26.4% |
| FY2023 | Dec 31, 2023 | $13.62M | +13.2% |
| FY2022 | Dec 31, 2022 | $12.03M | +6.0% |
| FY2021 | Dec 31, 2021 | $11.36M | +1170.9% |
| FY2020 | Dec 31, 2020 | $893.80K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.39M | +154.1% |
| Q1 FY2026 | Mar 31, 2026 | $10.84M | +3.1% |
| Q4 FY2025 | Dec 31, 2025 | $6.36M | -11.6% |
| Q3 FY2025 | Sep 30, 2025 | $7.65M | +82.6% |
| Q2 FY2025 | Jun 30, 2025 | $5.27M | +71.4% |
| Q1 FY2025 | Mar 31, 2025 | $10.51M | +282.1% |
| Q4 FY2024 | Dec 31, 2024 | $7.19M | +139.5% |
| Q3 FY2024 | Sep 30, 2024 | $4.19M | +29.9% |
| Q2 FY2024 | Jun 30, 2024 | $3.08M | -32.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.75M | -3.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.00M | -1.7% |
| Q3 FY2023 | Sep 30, 2023 | $3.23M | +8.2% |
| Q2 FY2023 | Jun 30, 2023 | $4.54M | +52.1% |
| Q1 FY2023 | Mar 31, 2023 | $2.85M | -5.4% |
| Q4 FY2022 | Dec 31, 2022 | $3.05M | +28.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.98M | +22.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.98M | +1214.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.02M | +2402.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.38M | +805.3% |
| Q1 FY2021 | Mar 31, 2021 | $2.43M | +759.0% |
| Q4 FY2020 | Dec 31, 2020 | $226.94K | – |
| Q3 FY2020 | Sep 30, 2020 | $120.57K | – |
| Q2 FY2020 | Jun 30, 2020 | $263.18K | – |
| Q1 FY2020 | Mar 31, 2020 | $283.11K | – |
See a number that looks wrong?